Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 8
Therapeutics and Clinical Risk Management
ISSN: 1178-203X
- View all (2305)
- Volume 19, 2023 (88)
- Volume 18, 2022 (104)
- Volume 17, 2021 (134)
- Volume 16, 2020 (134)
- Volume 15, 2019 (154)
- Volume 14, 2018 (271)
- Volume 13, 2017 (188)
- Volume 12, 2016 (217)
- Volume 11, 2015 (210)
- Volume 10, 2014 (113)
- Volume 9, 2013 (57)
- Volume 8, 2012 (47)
- Volume 7, 2011 (59)
- Volume 6, 2010 (66)
- Volume 5, 2009 (102)
- Volume 4, 2008 (148)
- Volume 3, 2007 (126)
- Volume 2, 2006 (47)
- Volume 1, 2005 (40)
Archive: Volume 8, 2012
Interventions performed by community pharmacists in one Canadian province: a cross-sectional study
Young SW, Bishop LD, Conway A
Therapeutics and Clinical Risk Management 2012, 8:415-421
Published Date: 6 December 2012
Glucarpidase to combat toxic levels of methotrexate in patients
Green JM
Therapeutics and Clinical Risk Management 2012, 8:403-413
Published Date: 22 November 2012
Appropriateness of administration of nasogastric medication and preliminary intervention
Zhu LL, Xu LC, Wang HQ, Jin JF, Wang HF, Zhou Q
Therapeutics and Clinical Risk Management 2012, 8:393-401
Published Date: 20 November 2012
Consequences of neurologic lesions assessed by Barthel Index after Botox® injection may be underestimated
Dionyssiotis Y, Kiourtidis D, Karvouni A, Kaliontzoglou A, Kliafas I
Therapeutics and Clinical Risk Management 2012, 8:385-391
Published Date: 19 October 2012
Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy
Rizzardini G, Bonfanti P, Carenzi L, Coen M, Orlando G, Di Matteo S, Colombo GL
Therapeutics and Clinical Risk Management 2012, 8:377-384
Published Date: 17 September 2012
Extreme intrafamilial variability of Saudi brothers with primary hyperoxaluria type 1
Alfadhel M, Alhasan KA, Alotaibi M, Al Fakeeh K
Therapeutics and Clinical Risk Management 2012, 8:373-376
Published Date: 28 August 2012
Efficacy of serum chitotriosidase activity in early treatment of patients with active tuberculosis and a negative sputum smear
Tasci C, Tapan S, Ozkaya S, Demirer E, Deniz O, Balkan A, Ozkan M, Inan I, Kurt I, Bilgic H
Therapeutics and Clinical Risk Management 2012, 8:369-372
Published Date: 27 August 2012
Treatment options for postmenopausal osteoporosis
Walsh GM
Therapeutics and Clinical Risk Management 2012, 8:367-368
Published Date: 28 August 2012
Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole
Corcia P, Gordon PH
Therapeutics and Clinical Risk Management 2012, 8:359-366
Published Date: 27 August 2012
The first case of cutaneous infection with Mycobacterium parascrofulaceum
Zong WK, Zhang XD, Wang HS, Xu XL, Wang QL, Tian WW, Jin YL, Wu QX, Tang MY
Therapeutics and Clinical Risk Management 2012, 8:353-358
Published Date: 15 August 2012
Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
Chen Y, Han F
Therapeutics and Clinical Risk Management 2012, 8:343-351
Published Date: 11 July 2012
Training in peroral endoscopic myotomy (POEM) for esophageal achalasia
Eleftheriadis N, Inoue H, Ikeda H, Onimaru M, Yoshida A, Hosoya T, Maselli R, Kudo S
Therapeutics and Clinical Risk Management 2012, 8:329-342
Published Date: 23 July 2012
Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
Wiwanitkit V
Therapeutics and Clinical Risk Management 2012, 8:323-328
Published Date: 22 June 2012
Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data
Bloomgren G, Sperling B, Cushing K, Wenten M
Therapeutics and Clinical Risk Management 2012, 8:313-321
Published Date: 20 June 2012
Knowledge of adverse drug reaction reporting in first year postgraduate doctors in a medical college
Upadhyaya P, Seth V, Moghe VV, Sharma M, Ahmed M
Therapeutics and Clinical Risk Management 2012, 8:307-312
Published Date: 19 June 2012
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P
Therapeutics and Clinical Risk Management 2012, 8:295-306
Published Date: 19 June 2012
Influence of treatment with alendronate on the speed of sound, an ultrasound parameter, of the calcaneus in postmenopausal Japanese women with osteoporosis: a clinical practice-based observational study
Iwamoto J, Takada T, Sato Y, Matsumoto H
Therapeutics and Clinical Risk Management 2012, 8:287-293
Published Date: 20 June 2012
Difficult airway and difficult intubation in postintubation tracheal stenosis: a case report and literature review
Zarogoulidis P, Kontakiotis T, Tsakiridis K, Karanikas M, Simoglou C, Porpodis K, Mitrakas A, Esebidis A, Konoglou M, Katsikogiannis N, Zervas V, Aggelopoulou C, Mikroulis D, Zarogoulidis K
Therapeutics and Clinical Risk Management 2012, 8:279-286
Published Date: 27 June 2012
Duloxetine in the management of chronic musculoskeletal pain
Smith HS, Smith EJ, Smith BR
Therapeutics and Clinical Risk Management 2012, 8:267-277
Published Date: 19 June 2012
Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility
Cavalli L, Brandi ML
Therapeutics and Clinical Risk Management 2012, 8:253-266
Published Date: 11 June 2012
Prevention and management of accidental foreign body ingestion and aspiration in orthodontic practice
Umesan UK, Chua KL, Balakrishnan P
Therapeutics and Clinical Risk Management 2012, 8:245-252
Published Date: 23 May 2012
Pain management with morphine: variation in analgesic response secondary to genetic polymorphisms
Kapoor S
Therapeutics and Clinical Risk Management 2012, 8:243-244
Published Date: 21 May 2012
Pharmacological management of binge eating disorder: current and emerging treatment options
McElroy SL, Guerdjikova AI, Mori N, O’Melia AM
Therapeutics and Clinical Risk Management 2012, 8:219-241
Published Date: 8 May 2012
The changing landscape of opioid prescribing: long-acting and extended-release opioid class-wide Risk Evaluation and Mitigation Strategy
Gudin JA
Therapeutics and Clinical Risk Management 2012, 8:209-217
Published Date: 1 May 2012
Role of gabapentin enacarbil XR in restless legs syndrome
Sivam S, Yee BJ
Therapeutics and Clinical Risk Management 2012, 8:201-208
Published Date: 1 May 2012
Five-year follow-up of a woman with pregnancy and lactation-associated osteoporosis and vertebral fractures
Iwamoto J , Sato Y, Uzawa M, Matsumoto H
Therapeutics and Clinical Risk Management 2012, 8:195-199
Published Date: 10 April 2012
Maximizing neuroprotection: where do we stand?
Kuffler DP
Therapeutics and Clinical Risk Management 2012, 8:185-194
Published Date: 10 April 2012
Interdisciplinary three-step strategy to treat aortic stenosis and coronary artery disease in a patient with end-stage chronic obstructive pulmonary disease
Michel S, Bigdeli AK, Beiras-Fernandez A, Schmitz C, Wolf M, Sodian R, Kaczmarek I
Therapeutics and Clinical Risk Management 2012, 8:181-183
Published Date: 11 April 2012
Optimal management of giant cell arteritis and polymyalgia rheumatica
Charlton R
Therapeutics and Clinical Risk Management 2012, 8:173-179
Published Date: 5 April 2012
Measurement complexity of adherence to medication
Galato D, Schuelter-Trevisol F, Piovezan AP
Therapeutics and Clinical Risk Management 2012, 8:169-171
Published Date: 2 April 2012
Human normal immunoglobulin in the treatment of primary immunodeficiency diseases
Wood P
Therapeutics and Clinical Risk Management 2012, 8:157-167
Published Date: 2 April 2012
Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections
Goodman JJ, Martin SI
Therapeutics and Clinical Risk Management 2012, 8:149-156
Published Date: 26 March 2012
Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
Werth S, Halbritter K, Beyer-Westendorf J
Therapeutics and Clinical Risk Management 2012, 8:139-147
Published Date: 23 March 2012
Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
Hooper CY, Smith WJ
Therapeutics and Clinical Risk Management 2012, 8:131-137
Published Date: 16 March 2012
Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O'Regan C, Mills EJ
Therapeutics and Clinical Risk Management 2012, 8:105-130
Published Date: 9 March 2012
Ruxolitinib for the treatment of myelofibrosis: its clinical potential
Ostojic A, Vrhovac R, Verstovsek S
Therapeutics and Clinical Risk Management 2012, 8:95-103
Published Date: 1 March 2012
NIHSS and acute complications after anterior and posterior circulation strokes
Boone M, Chillon JM, Garcia PY, Canaple S, Lamy C, Godefroy O, Bugnicourt JM
Therapeutics and Clinical Risk Management 2012, 8:87-93
Published Date: 27 February 2012
Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus
Hagihara M, Umemura T, Mori T, Mikamo H
Therapeutics and Clinical Risk Management 2012, 8:79-86
Published Date: 17 February 2012
Noninvasive radioelectric asymmetric conveyor brain stimulation treatment improves balance in individuals over 65 suffering from neurological diseases: pilot study
Fontani V, Rinaldi S, Castagna A, Margotti ML
Therapeutics and Clinical Risk Management 2012, 8:73-78
Published Date: 17 February 2012
Coronary artery disease in Africa and the Middle East
Almahmeed W, Arnaout MS, Chettaoui R, Ibrahim M, Kurdi MI, Taher MA, Mancia G
Therapeutics and Clinical Risk Management 2012, 8:65-72
Published Date: 16 February 2012
Metabolic syndrome in a sample of the 6- to 16-year-old overweight or obese pediatric population: a comparison of two definitions
Saffari F, Jalilolghadr S, Esmailzadehha N, Azinfar P
Therapeutics and Clinical Risk Management 2012, 8:55-63
Published Date: 2 February 2012
Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility
Witkiewitz K, Saville KA, Hamreus K
Therapeutics and Clinical Risk Management 2012, 8:45-53
Published Date: 1 February 2012
New treatment options for lupus – a focus on belimumab
Chiche L, Jourde N, Thomas G, Bardin N, Bornet C, Darque A, Mancini J
Therapeutics and Clinical Risk Management 2012, 8:33-43
Published Date: 26 January 2012
Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral palsy and other neurologic conditions
Zeller RS, Davidson J, Lee HM, Cavanaugh PF
Therapeutics and Clinical Risk Management 2012, 8:25-32
Published Date: 25 January 2012
Randomized Phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions
Zeller RS, Lee HM, Cavanaugh PF, Davidson J
Therapeutics and Clinical Risk Management 2012, 8:15-23
Published Date: 25 January 2012
Clinical utility of adjunctive retigabine in partial onset seizures in adults
Rejdak K, Luszczki JJ, Błaszczyk B, Chwedorowicz R, Czuczwar SJ
Therapeutics and Clinical Risk Management 2012, 8:7-14
Published Date: 20 January 2012
Aripiprazole in the acute and maintenance phase of bipolar I disorder
Zupancic M, Gonzalez ML
Therapeutics and Clinical Risk Management 2012, 8:1-6
Published Date: 12 January 2012